Dyne Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Dyne Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $892.00K, a 68.09% decline year-over-year.
- Dyne Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.31M, a 122.96% increase year-over-year.
- Dyne Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.25M, a 93.06% decline year-over-year.
- Dyne Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $2.79M, a 34.74% decline year-over-year.
- Dyne Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $8.00M, a 78.41% decline from fiscal 2024.
- Dyne Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $37.04M, a 1796.72% increase from fiscal 2023.
- Dyne Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $1.95M, a 269.19% increase from fiscal 2022.
- Dyne Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $529.00K, a 9.42% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $892.00K 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $1.31M 10-Q · filed 2026-07-29 | |
| 2025-12-31 | $8.00M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.25M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $2.79M 10-Q · filed 2026-07-29 | |
| 2025-03-31 | $588.00K 10-Q · filed 2026-07-29 | |
| 2024-12-31 | $37.04M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $18.01M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $4.28M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $10.92M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $1.95M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $453.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $764.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $587.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $529.00K 10-K · filed 2025-02-27 | |
| 2022-09-30 | $70.00K 10-Q · filed 2023-10-30 | |
| 2022-06-30 | $99.00K 10-Q · filed 2023-10-30 | |
| 2022-03-31 | $18.00K 10-Q · filed 2023-10-30 | |
| 2021-12-31 | $584.00K 10-K · filed 2023-03-02 | |
| 2021-09-30 | $457.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $25.00K 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $13.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $30.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $24.00K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |